Clinical trials: Relapsed T-Cell Lymphoma
Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete…
- Conditions
- Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma
- Trial name
- NCT06271057
- Testing
- golcadomide
- Where
- 13 sites in France
- Volunteers
- 65 people
- Sponsor
- The Lymphoma Academic Research Organisation
Cancer
Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer
RATIONALE: Telephone counseling by trained counselors may enhance the well-being and quality of life of patients who have undergone stem cell transplantation for cancer.
- Trial name
- NCT00049465
- Testing
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Where
- 9 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL.
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma
- Trial name
- NCT02631044
- Testing
- JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Where
- 14 sites in United States
- Volunteers
- 387 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
T-ALL, Lymphoma, T-Cell
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.
- Trial name
- NCT05398614
- Testing
- SENL101
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Lymphoma
MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT03932955
- Testing
- MC-19PD1 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to…
- Trial name
- NCT04134325
- Testing
- Nivolumab, Pembrolizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Hodgkin Lymphoma
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat)…
- Trial name
- COMBOSTAT (NCT00837174)
- Testing
- Vorinostat in combination with Bortezomib
- Sponsor
- The Methodist Hospital Research Institute
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D).
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma, Follicular Lymphoma Grade 3A
- Trial name
- NCT05326243
- Testing
- CD19-targeted chimeric antigen receptor T-cell
- Where
- 5 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
Extranodal NK/T-cell Lymphoma, Nasal Type
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma
This is an open-label, multi-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 in subjects with relapsed or refractory extranodal NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according…
- Trial name
- NCT03363555
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Peripheral T-Cell Lymphoma Refractory
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
An Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
- Trial name
- NCT07598578
- Testing
- Azacitidine (AZA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Acute T Lymphpblastic Leukemia/Lymphoma
VHAG in Treating R/R T-ALL/LBL
Acute T cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive type of leukemia that results from the malignant evolution of T-lineage progenitor cells at different differentiation stages.
- Trial name
- NCT06742463
- Testing
- Venetoclax, homoharringtonine, Cytarabine (Ara-C)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
- Trial name
- NCT00873093
- Testing
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone
- Where
- 171 sites in United States, Australia and 2 more
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Cytomegalovirus Infections, Acute Leukemia
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Letermovir is approved for the primary prevention of Cytomegalovirus (CMV) reactivation and infection in hematopoietic stem cell transplant recipients.
- Conditions
- Cytomegalovirus Infections, Acute Leukemia, B Cell Lymphoma
- Trial name
- CMV CAR-T (NCT06058858)
- Where
- 3 sites in France
- Volunteers
- 250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma, T Cell, Peripheral, T-cell Lymphoma
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
Background: T-cell lymphoma is a blood cancer that affects immune system cells. People tend to survive less than 1 year if this disease does not respond to treatment (is refractory) or comes back after treatment (relapses).
- Conditions
- Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT07388563
- Testing
- azacitidine, abatacept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
RATIONALE: Listening to relaxing music during a bone marrow biopsy may be effective in reducing anxiety and pain. PURPOSE: This randomized clinical trial is studying how well music works in reducing anxiety and pain in adult…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00376922
- Testing
- music therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that has come back (relapsed) or…
- Trial name
- NCT04484012
- Testing
- Acalabrutinib, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase II trial to study the effectiveness of 506U78 in treating patients with refractory or relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT00003545
- Testing
- nelarabine
- Where
- 91 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory B-cell Lymphomas
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
The present study is an exploratory study. Patients who meeting the enrollment conditions for relapsed or refractory B-cell lymphoma receive a single intravenous dose of CD20-CART cells.
- Trial name
- NCT03576807
- Testing
- CD20 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xin Wang
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2.
- Trial name
- NCT04362007
- Testing
- ASTX660
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory
- Trial name
- NCT04603872
- Testing
- CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University